Iridex to Report Third Quarter Financial Results on November 14, 2023
October 26 2023 - 4:22PM
Iridex Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, today announced the Company will
release financial results for the third quarter of 2023 after the
close of trading on Tuesday, November 14, 2023.
About IridexIridex Corporation is a
worldwide leader in developing, manufacturing, and marketing
innovative and versatile laser-based medical systems, delivery
devices and consumable instrumentation for the ophthalmology
market. The Company’s proprietary MicroPulse® technology
delivers a differentiated treatment that provides safe, effective,
and proven treatment for targeted sight-threatening eye conditions.
Iridex’s current product line is used for the treatment of glaucoma
and diabetic macular edema (DME) and other retinal
diseases. Iridex products are sold in the United
States through a direct sales force and internationally
primarily through a network of independent distributors into more
than 100 countries. For further information, visit
the Iridex website at www.iridex.com.
Investor Relations Contact:Philip
TaylorGilmartin Groupinvestors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Apr 2024 to May 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From May 2023 to May 2024